Key takeaways
Mayzent (siponimod) and Tysabri (natalizumab) are both used to treat relapsing forms of multiple sclerosis (MS), but they have some key differences. Of note, Tysabri has an additional indication for Crohn's Disese (CD). Mayzent is taken orally as a tablet once a day, while Tysabri is given as an intravenous (IV) infusion once a month. Mayzent requires genetic testing before starting treatment to determine the appropriate dose, whereas Tysabri requires enrollment in the TOUCH Prescribing Program due to its risk of serious infections like progressive multifocal leukoencephalopathy (PML). Mayzent can cause side effects such as headache, high blood pressure, and falls, while Tysabri can lead to headaches, fatigue, and urinary tract infections. Additionally, Mayzent is not safe during pregnancy, and Tysabri's safety during pregnancy is not well established. Both are only available as brand-name medications.
